Araz Marachelian

Araz Marachelian, MD is an Assistant Professor of Clinical Pediatrics at the Keck School of Medicine of the University of Southern California, affiliated with Children's Hospital Los Angeles. His clinical and research focus centers on pediatric oncology, particularly neuroblastoma treatment and clinical trials. He has held leadership roles in the New Approaches to Neuroblastoma Therapy (NANT) consortium and specializes in developing novel therapeutic strategies for high-risk pediatric cancers.

His research explores biomarkers for neuroblastoma prognosis, drug resistance mechanisms, and radioisotope therapies. Notable achievements include pioneering studies on lorlatinib resistance and identifying predictive biomarkers for 131I-MIBG efficacy. He has been recognized with prestigious awards including the NCI Cancer Clinical Investigator Team Leadership Award and multiple listings in 'Top Doctors' rankings.

Dr. Marachelian's work bridges clinical care and translational research, emphasizing patient-centered outcomes and improving therapeutic approaches for children with relapsed/refractory cancers. His team collaborates extensively with institutions like the Children’s Oncology Group and has contributed to over 80 peer-reviewed publications since 2005.